We are analyzing https://link.springer.com/article/10.1007/s00262-008-0480-y.

Title:
Cancer treatment: the combination of vaccination with other therapies | Cancer Immunology, Immunotherapy
Description:
Harnessing of the immune system by the development of ‘therapeutic’ vaccines, for the battle against cancer has been the focus of tremendous research efforts over the past two decades. As an illustration of the impressive amounts of data gathered over the past years, numerous antigens expressed on the surface of cancer cells, have been characterized. To this end, recent years research has focussed on characterization of antigens that play an important role for the growth and survival of cancer cells. Anti-apoptotic molecules like survivin that enhance the survival of cancer cells and facilitate their escape from cytotoxic therapies represent prime vaccination candidates. The characterization of a high number of tumor antigens allow the concurrent or serial immunological targeting of different proteins associated with such cancer traits. Moreover, while vaccination in itself is a promising new approach to fight cancer, the combination with additional therapy could create a number of synergistic effects. Herein we discuss the possibilities and prospects of vaccination when combined with other treatments. In this regard, cell death upon drug exposure may be immunogenic or non-immunogenic depending on the specific chemotherapeutics. Also, chemotherapy represents one of several options available for clearance of CD4+ Foxp3+ regulatory T cells. Moreover, therapies based on monoclonal antibodies may have synergistic potential in combination with vaccination, both when used for targeting of tumor cells and endothelial cells. The efficacy of therapeutic vaccination against cancer will over the next few years be studied in settings taking advantage of strategies in which vaccination is combined with other treatment modalities. These combinations should be based on current knowledge not only regarding the biology of the cancer cell per se, but also considering how treatment may influence the malignant cell population as well as the immune system.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

cancer, cells, google, scholar, pubmed, article, cas, tumor, vaccination, cell, immune, targeting, proteins, responses, patients, survivin, therapy, chemotherapy, apoptosis, immunotherapy, combination, antigens, resistance, drug, immunol, treatment, data, protein, thor, straten, therapeutic, vaccines, cytotoxic, specific, strategies, antigen, angiogenesis, becker, death, mechanisms, bcl, clinical, andersen, growth, endothelial, response, lymphocytes, rev, therapies, effects,

Topics {✒️}

t-cell-receptor gene therapy wild-type p53-derived peptide article download pdf vaccine-induced anti-tumor response existing host-tumour interaction cytolytic t-cell attack cyclophosphamide-facilitated adoptive immunotherapy anti-angiogenic therapy utilizes nonpeptidic small-molecule antagonists universal anti-tumor vaccine discovery-driven translational research enhances cd28-dependent proliferation reduction/oxidation regulate immunity anti-angiogenic therapy targets adoptive t-cell transfer apoptosis protein ml-iap underlie tumor-specific differences cd4+ foxp3+ regulatory hla-a2402-restricted cytotoxic intra-cellular protein involved anti-cancer immune responses anthracyclin-treated tumor cells inhibiting anti-tumor responses immune cell-mediated apoptosis multi-epitope setting large-scale studies antigen-negative cancer cells privacy choices/manage cookies tumor-specific drug inactivation survivin peptides/hla complexes peptide-based vaccines genetically stable nature anti-angiogenic therapy anti-cancer vaccination strategies article andersen anti-cancer vaccines full access low dose cyclophosphamide xiap–sirna enhanced minimal size depend dna-damaging agents t-cell clones anti-angiogenic therapeutics common apoptotic pathways colorectal tumor-infiltrating active immune therapy metastatic colon cancer integrating tumor vaccines regulating endothelial proliferation developing cancer vaccines

Questions {❓}

Folkman J (2007) Angiogenesis: an organizing principle for drug discovery?
Monsurro V, Wang E, Panelli MC, Nagorsen D, Jin P, Katia Z, Smith K, Ngalame Y, Even J, Marincola FM (2003) Active-specific immunization against melanoma: is the problem at the receiving end?
Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A (2002) Cancer immunotherapy with peptide-based vaccines: what have we achieved?
Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL (2001) Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Cancer treatment: the combination of vaccination with other therapies
         description:Harnessing of the immune system by the development of ‘therapeutic’ vaccines, for the battle against cancer has been the focus of tremendous research efforts over the past two decades. As an illustration of the impressive amounts of data gathered over the past years, numerous antigens expressed on the surface of cancer cells, have been characterized. To this end, recent years research has focussed on characterization of antigens that play an important role for the growth and survival of cancer cells. Anti-apoptotic molecules like survivin that enhance the survival of cancer cells and facilitate their escape from cytotoxic therapies represent prime vaccination candidates. The characterization of a high number of tumor antigens allow the concurrent or serial immunological targeting of different proteins associated with such cancer traits. Moreover, while vaccination in itself is a promising new approach to fight cancer, the combination with additional therapy could create a number of synergistic effects. Herein we discuss the possibilities and prospects of vaccination when combined with other treatments. In this regard, cell death upon drug exposure may be immunogenic or non-immunogenic depending on the specific chemotherapeutics. Also, chemotherapy represents one of several options available for clearance of CD4+ Foxp3+ regulatory T cells. Moreover, therapies based on monoclonal antibodies may have synergistic potential in combination with vaccination, both when used for targeting of tumor cells and endothelial cells. The efficacy of therapeutic vaccination against cancer will over the next few years be studied in settings taking advantage of strategies in which vaccination is combined with other treatment modalities. These combinations should be based on current knowledge not only regarding the biology of the cancer cell per se, but also considering how treatment may influence the malignant cell population as well as the immune system.
         datePublished:2008-02-20T00:00:00Z
         dateModified:2008-02-20T00:00:00Z
         pageStart:1735
         pageEnd:1743
         license:https://creativecommons.org/licenses/by-nc/2.0
         sameAs:https://doi.org/10.1007/s00262-008-0480-y
         keywords:
            Vaccination
            Conventional treatment
            Combination
            Cancer
            Chemotherapy
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0480-y/MediaObjects/262_2008_480_Fig1_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:57
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Mads Hald Andersen
               affiliation:
                     name:Herlev University Hospital
                     address:
                        name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rikke Bæk Sørensen
               affiliation:
                     name:Herlev University Hospital
                     address:
                        name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David Schrama
               affiliation:
                     name:University Hospital of Würzburg
                     address:
                        name:Department of Dermatology, University Hospital of Würzburg, Würzburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Inge Marie Svane
               affiliation:
                     name:Herlev University Hospital
                     address:
                        name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jürgen C. Becker
               affiliation:
                     name:University Hospital of Würzburg
                     address:
                        name:Department of Dermatology, University Hospital of Würzburg, Würzburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Per thor Straten
               affiliation:
                     name:Herlev University Hospital
                     address:
                        name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Cancer treatment: the combination of vaccination with other therapies
      description:Harnessing of the immune system by the development of ‘therapeutic’ vaccines, for the battle against cancer has been the focus of tremendous research efforts over the past two decades. As an illustration of the impressive amounts of data gathered over the past years, numerous antigens expressed on the surface of cancer cells, have been characterized. To this end, recent years research has focussed on characterization of antigens that play an important role for the growth and survival of cancer cells. Anti-apoptotic molecules like survivin that enhance the survival of cancer cells and facilitate their escape from cytotoxic therapies represent prime vaccination candidates. The characterization of a high number of tumor antigens allow the concurrent or serial immunological targeting of different proteins associated with such cancer traits. Moreover, while vaccination in itself is a promising new approach to fight cancer, the combination with additional therapy could create a number of synergistic effects. Herein we discuss the possibilities and prospects of vaccination when combined with other treatments. In this regard, cell death upon drug exposure may be immunogenic or non-immunogenic depending on the specific chemotherapeutics. Also, chemotherapy represents one of several options available for clearance of CD4+ Foxp3+ regulatory T cells. Moreover, therapies based on monoclonal antibodies may have synergistic potential in combination with vaccination, both when used for targeting of tumor cells and endothelial cells. The efficacy of therapeutic vaccination against cancer will over the next few years be studied in settings taking advantage of strategies in which vaccination is combined with other treatment modalities. These combinations should be based on current knowledge not only regarding the biology of the cancer cell per se, but also considering how treatment may influence the malignant cell population as well as the immune system.
      datePublished:2008-02-20T00:00:00Z
      dateModified:2008-02-20T00:00:00Z
      pageStart:1735
      pageEnd:1743
      license:https://creativecommons.org/licenses/by-nc/2.0
      sameAs:https://doi.org/10.1007/s00262-008-0480-y
      keywords:
         Vaccination
         Conventional treatment
         Combination
         Cancer
         Chemotherapy
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0480-y/MediaObjects/262_2008_480_Fig1_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:57
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Mads Hald Andersen
            affiliation:
                  name:Herlev University Hospital
                  address:
                     name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rikke Bæk Sørensen
            affiliation:
                  name:Herlev University Hospital
                  address:
                     name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David Schrama
            affiliation:
                  name:University Hospital of Würzburg
                  address:
                     name:Department of Dermatology, University Hospital of Würzburg, Würzburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Inge Marie Svane
            affiliation:
                  name:Herlev University Hospital
                  address:
                     name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jürgen C. Becker
            affiliation:
                  name:University Hospital of Würzburg
                  address:
                     name:Department of Dermatology, University Hospital of Würzburg, Würzburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Per thor Straten
            affiliation:
                  name:Herlev University Hospital
                  address:
                     name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:57
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Herlev University Hospital
      address:
         name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
         type:PostalAddress
      name:Herlev University Hospital
      address:
         name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
         type:PostalAddress
      name:University Hospital of Würzburg
      address:
         name:Department of Dermatology, University Hospital of Würzburg, Würzburg, Germany
         type:PostalAddress
      name:Herlev University Hospital
      address:
         name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
         type:PostalAddress
      name:University Hospital of Würzburg
      address:
         name:Department of Dermatology, University Hospital of Würzburg, Würzburg, Germany
         type:PostalAddress
      name:Herlev University Hospital
      address:
         name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Mads Hald Andersen
      affiliation:
            name:Herlev University Hospital
            address:
               name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Rikke Bæk Sørensen
      affiliation:
            name:Herlev University Hospital
            address:
               name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:David Schrama
      affiliation:
            name:University Hospital of Würzburg
            address:
               name:Department of Dermatology, University Hospital of Würzburg, Würzburg, Germany
               type:PostalAddress
            type:Organization
      name:Inge Marie Svane
      affiliation:
            name:Herlev University Hospital
            address:
               name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Jürgen C. Becker
      affiliation:
            name:University Hospital of Würzburg
            address:
               name:Department of Dermatology, University Hospital of Würzburg, Würzburg, Germany
               type:PostalAddress
            type:Organization
      name:Per thor Straten
      affiliation:
            name:Herlev University Hospital
            address:
               name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
      name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
      name:Department of Dermatology, University Hospital of Würzburg, Würzburg, Germany
      name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark
      name:Department of Dermatology, University Hospital of Würzburg, Würzburg, Germany
      name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark

External Links {🔗}(261)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Pace
Prism.js

CDN Services {📦}

Crossref

5.2s.

LINK . SPRINGER . COM {}